Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab in Metastatic Renal Cell Carcinoma
NCT00100685Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jan 2005
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of volociximab in renal cell carcinoma (RCC), sponsored by Abbott Laboratories. Started Jan 2005; status: terminated.
02
Drugs
volociximab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00100685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100685.